The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has provided additional funding in the amount of USD 587,995 to its contract with US-based biotechnology company Chrysalis BioTherapeutics, Inc., bringing the total contract award to develop TP508 as a therapeutic for COVID-19 patients to USD 1.5m, the company said.
Chrysalis is developing regenerative drugs that target vascular endothelial and progenitor cells.
The company, located in Galveston, TX. TP508 (rusalatide acetate), is licensed from The University of Texas Medical Branch at Galveston, TX.
Although TP508 has shown potential efficacy in stimulating early tissue repair in human clinical trials, it is not yet FDA-approved and is currently only available for investigational use.
Research reported in this press release was in whole or part supported with federal funds from NIAID under contract number HHSN272201700011C.
The content is solely the responsibility of the authors and Chrysalis BioTherapeutics, Inc. and does not necessarily represent official views of the National Institutes of Health or The University of Texas Medical Branch.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial